AD04

DRUG2 trials

Sponsors

Advantage Therapeutics GmbH, ADvantage Therapeutics

Conditions

Alzheimer Disease, Early Onsetearly Alzheimer’s disease

Phase 2

A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE

SuspendedCTIS2024-518523-30-00

Advantage Therapeutics GmbHearly Alzheimer’s disease

Start: 2023-11-08Target: 58Updated: 2025-01-30

Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE

Active, not recruitingNCT07107074

ADvantage TherapeuticsAlzheimer Disease, Early Onset

Start: 2023-11-08End: 2027-07-31Target: 122Updated: 2025-08-06